Valuation: Bicycle Therapeutics plc

Market Cap 277M 240M 224M 206M 389M 26.35B 393M 2.63B 1.03B 13.19B 1.04B 1.02B 43.67B P/E 2026 *
-1.49x
P/E 2027 * -1.72x
Enterprise Value -174M -151M -141M -129M -244M -16.55B -247M -1.65B -648M -8.28B -654M -639M -27.43B EV / Sales 2026 *
-10.7x
EV / Sales 2027 * -19.2x
Free-Float
71.25%
Yield 2026 *
-
Yield 2027 * -
1 day+0.76%
1 week+2.85%
Current month+2.85%
1 month-8.74%
3 months-18.98%
6 months-25.24%
Current year-43.93%
1 week 3.74
Extreme 3.745
4.02
1 month 3.74
Extreme 3.745
4.52
Current year 3.74
Extreme 3.745
7.34
1 year 3.74
Extreme 3.745
9.16
3 years 3.74
Extreme 3.745
28.67
5 years 3.74
Extreme 3.745
62.08
10 years 3.74
Extreme 3.745
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Date Insider Type Main position Quantity % Market Cap.
15/7/26 Free

CHIEF PROD & SUPPLY CHAIN OFF

60,000 0.1580%
15/7/26 Free

Chief Technology Officer

60,000 0.1580%
15/7/26 Free

Chief Operating Officer

60,000 0.1580%
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%+2.85%-49.49%-83.08% 277M
+4.35%+16.60%+58.11%+95.21% 64.9B
+2.83%-3.48%+24.97%+67.25% 54.05B
+0.91%-0.83%-17.01%-13.43% 23.16B
+0.27%-3.98%-11.28%+350.30% 21.46B
+2.22%+9.95%+31.44%-5.22% 21.25B
+0.75%+1.34%+32.22%-25.25% 17.94B
+9.88%+23.61%+222.87%+385.49% 17.03B
+2.18%+4.47%+19.70%+628.26% 14.99B
+1.25%+2.48%+51.36%+179.72% 14.25B
Average +2.55%+4.82%+36.29%+157.92% 24.93B
Weighted average by Cap. +2.98%+5.90%+42.27%+140.29%

Financials

2026 *2027 *
Net sales 16.31M 14.13M 13.17M 12.11M 22.87M 1.55B 23.12M 155M 60.75M 776M 61.27M 59.92M 2.57B 6.69M 5.79M 5.4M 4.97M 9.38M 636M 9.48M 63.46M 24.91M 318M 25.12M 24.57M 1.05B
Net income -186M -161M -150M -138M -261M -17.68B -264M -1.76B -692M -8.85B -698M -683M -29.29B -172M -149M -139M -128M -241M -16.38B -244M -1.63B -641M -8.19B -647M -633M -27.14B
Net Debt -451M -391M -364M -335M -633M -42.91B -640M -4.28B -1.68B -21.47B -1.69B -1.66B -71.1B -406M -352M -328M -301M -569M -38.59B -575M -3.85B -1.51B -19.31B -1.52B -1.49B -63.95B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
05/08/26 USD 3.970 +0.76% 287,691
04/08/26 USD 3.940 +1.81% 179,671
03/08/26 USD 3.870 +0.26% 340,369
31/07/26 USD 3.860 -3.74% 336,076
30/07/26 USD 4.010 +3.89% 418,975
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.970USD
Average target price
9.857USD
Spread / Average Target
+148.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock